Industry News

Indivior, and MonoSol Rx conspired to block generic competitors for Suboxone by switching the drug from a tablet to a dissolving film."/>
Maryland among 36 states suing makers of heroin addiction treatment drug Suboxone for antitrust violations [The Baltimore Sun]
Universal American Corp.. Best has affirmed the Financial Strength Rating of B+ and the Long-Term ICR of“ bbb-” of American Progressive Life& Health Insurance Company of New York. Best has affirmed the FSR of B and the Long-Term ICR of“ bb+” of SelectCare of Texas, Inc.."/>
A.M. Best Withdraws Credit Ratings of Universal American Corp. and Its Subsidiaries
Achillion Pharmaceuticals, Inc. announced that updated interim results were presented today in an ePoster describing a phase 2 study being conducted by Alios BioPharma Inc., part of the Janssen..."/>
Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV
Veracyte, Inc. today announced new data suggesting the potential to enhance the performance of the Afirma Gene Expression Classifier in thyroid cancer diagnosis by combining the test's proven RNA expression-based capabilities with gene variant and fusion information– all on a single, robust RNA sequencing platform. Such enhancements could help to further reduce the number of patients who undergo unnecessary surgery..."/>
Veracyte Presents Data Demonstrating Potential to Enhance Afirma® Gene Expression Classifier Using an RNA Sequencing Platform
Celldex Therapeutics, Inc. announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will participate in a fireside chat at the Leerink Partners Rare Disease& Immuno-Oncology Roundtable on Thursday, September 29, 2016 at 2:00 p.m. EDT in New York.. The live webcast will be available on the "Events& Presentations" page of the "Investors& Media" section of..."/>
Celldex Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
Biostar Pharmaceuticals, Inc. has agreed to acquire all equity interest in China-based health product maker Xianyang Yongsheng Health Products Co., Ltd. for a cash payment and issuance of shares of Biostar's restricted common stock, the company said. Biostar said that the amount of the cash payment is to be determined following completion of the due diligence review of the target."/>
Biostar Pharmaceuticals to Acquire Chinese Health Product Maker Xianyang Yongsheng
Biocept, Inc., a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces that Lyle Arnold, Ph.D., Chief Scientific Officer of Biocept, will present at two SelectBio conferences being held between September 26-30 in San Diego. Arnold's presentations will focus on Biocept's patented Target-Selector™..."/>
Biocept's Proprietary Liquid Biopsy Platform to be Featured at Two Upcoming Molecular Diagnostics Conferences
Pulmatrix, Inc. today announced that a recent white paper, What is the future of inhalation delivery? ,by global research and consulting firm Envigo predicts rapid growth for drugs that are delivered to the lungs through inhalation. "The global market for inhalation drug delivery methodology alone is expected to reach US $48 bn by 2016," says the report."/>
Pulmatrix Highlights Recent Report Predicting Rapid Growth for Inhaled Drug Delivery Methods
Synergy Pharmaceuticals Inc. today announced the company will present at the OctoberINVESTfest Conference on Wednesday, September 28, 2016 at 11:30 a.m. Eastern Time at the New York Academy of Sciences in New York. A live webcast of the presentation will be accessible through the Investor Relations section of the company’ s website at www.synergypharma.com. A replay of the webcast will be available on Synergy’ s website for 60 days following the conference."/>
Synergy Pharmaceuticals to Present at OctoberINVESTfest 2016
Chembio Diagnostics, Inc., a leader in point-of-care diagnostic tests for infectious diseases, today announced that the Company has entered into an exclusive distribution agreement with Isla Lab LLC that includes both Puerto Rico and the U.S. Chembio recently announced that it had entered into an exclusive distribution agreement with Isla Lab Caribbean that included the 25 Caribbean nations. With today’ s announcement, Isla Lab becomes Chembio’ s..."/>
Chembio Expands Exclusive Distribution Agreements with Isla Lab to Include Puerto Rico and U.S. Virgin Islands
TG Therapeutics, Inc. today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the Ladenburg Thalmann 2016 Healthcare Conference being held at the Sofitel Hotel in New York, NY. The presentation is scheduled to take place on Tuesday September 27, 2016 at 11:30am ET. A live webcast of this presentation will be available on the Events page, located within the Investors& Media section, of the..."/>
TG Therapeutics, Inc. to Present at the Ladenburg Thalmann 2016 Healthcare Conference
CytoSorbents Corporation, a critical care immunotherapy leader commercializing its flagship CytoSorb ® cytokine adsorber to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced that it has signed an exclusive distribution agreement with Armaghan Salamat Kish Group to distribute CytoSorb ® for all critical care, cardiac surgery, and other hospital applications in..."/>
CytoSorbents Expands CytoSorb® into Iran with Partner Arsak
Pfizer Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended has expired with respect to Pfizer’ s pending acquisition of Medivation, Inc.. Pfizer now expects to complete the acquisition in the Third-Quarter 2016."/>
Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation
Mallinckrodt Pharmaceuticals, a leading global specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office has upheld the validity of commercially significant claims related to five patents covering gas delivery systems as well as methods of using such systems related to INOMAX ® gas, for inhalation. The USPTO decisions came in the context of Inter Partes Review proceedings,..."/>
Validity of Mallinckrodt's INOMAX® Patent Claims Upheld
Dynatronics Corporation today announced its financial results for the quarter ended June 30, 2016 and the full fiscal year ended June 30, 2016, will be released pre market open on Monday, September 26, 2016.. The company will hold a conference call at 8:30 AM EDT on Monday, September 26 to discuss the results with analysts and institutional investors. The call will include remarks by the company's management team as well as..."/>
Dynatronics Schedules Fourth Quarter and Full Year Financial Results Conference Call
AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced that it is presenting today at the inaugural MicroCap Leadership Summit, hosted by MicroCapClub, at the Westin Chicago Northwest Hotel in Itasca, Illinois. AMS's presentation is accessible on the "Investor Center" page of the American Shared Hospital Services website, www.ashs.com."/>
American Shared Hospital Services Presents at the MicroCap Leadership Summit
Intrexon Corporation, a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it has entered into Exclusive Channel Collaborations with two startups backed by the Harvest Intrexon Enterprise Fund, sponsored by Harvest Capital Strategies, LLC. Through Intrexon's proprietary ActoBiotics™ Lactococcus lactis platform, these companies will pursue new..."/>
Intrexon to Develop Disease-Modifying Therapies in New Collaborations with Harvest Intrexon Enterprise Fund
Venaxis ®, Inc., announced that on September 21, 2016, the Company approved the grant of stock options to six new employees, hired in connection with the Company's acquisition of BiOptix Diagnostics, Inc., to purchase an aggregate of 95,000 shares of common stock. The stock options were granted as inducement grants material to the new employees entering into employment with the Company, as permitted under NASDAQ Listing Rule 5635 (c)."/>
Venaxis Reports Option Inducement Grants for New Employees Under NASDAQ Listing Rule 5635(c)(4)
Catalyst Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing novel protease therapeutics to treat serious medical conditions in the field of hemostasis, today announced that Nassim Usman, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference, being held in New York City September 27, 2016.. Ladenburg Thalmann 2016..."/>
Catalyst Biosciences To Present at the Ladenburg Thalmann 2016 Healthcare Conference
Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has entered into a definitive agreement with institutional investors for an offering of shares of common stock with gross proceeds of approximately $4.6 million in a registered direct offering. The closing of the offering is expected to take place on or about September 27, 2016, subject to the satisfaction of..."/>
Apricus Biosciences Announces $4.6 Million Registered Direct Offering
Fortress Biotech company, announced today that James F. Oliviero, III, President and CEO of Checkpoint, will present at the Ladenburg Thalmann 2 nd Annual Healthcare Conference on Tuesday, September 27, 2016 at 11:00 AM ET. The conference will be held at the Sofitel Hotel in New York City.. A live webcast of the presentation will be available on the Company’ s website, www.checkpointtx.com on the Events page, located within the..."/>
Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology666 Articles
Consumer Discretionary609 Articles
Financials441 Articles
Health Care379 Articles
Industrials378 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.